Shots: Dicerna to receive $200M up front and up to $1.47B development, regulatory and commercial milestones and royalties based on the sales of DCR-HBVS. Roche to get WW license to […]readmore
Tags : Agreement
Shots: The companies collaborated to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal space The focus of the agreement is to merge Pear’s expertise […]readmore
Shots: The agreement allows CF patients aged ≥2yrs.with two copies of F508del mutation in CFTR gene to access Orkambi (lumacaftor/ivacaftor) and CF patients aged ≥12yrs. with either two or one […]readmore
Shots: Biomica collaborated with Weizmann Institute of Science to develop a selective treatment against antibiotic-resistant strains of Staphylococcus aureus infection, targeting a specific microbe while maintaining the microbiome of the […]readmore
Shots: Pear Therapeutics will solely be responsible for commercialization of its prescription digital therapeutics (PDTs), reSET and reSET-O, therapies to treat substance use disorder (SUD) and opioid use disorder (OUD) […]readmore
Shots: Alexion to get exclusive WW rights to develop and commercialize Elamipretide (SC) outside the US with an exclusive option to partner with Stealth for the development of Elamipretide based […]readmore
Shots: Biocon Biologics will perform all end-to-end development activities, IND filing, manufacturing and commercialization post-regulatory approval in its own authorized global markets for assets and will utilize Just – Evotec […]readmore
Shots: The program has two parts Growth Track, in which companies will receive €75 funding for co-creating solutions, as well as co-working space at Bayer’s Pharmaceuticals division headquarters in Berlin, […]readmore
Shots: Evotec will take care of medicinal chemistry, in vitro and in vivo pharmacology plus its development capabilities and expertise while Celmatix will utilize its novel drug target discovery based […]readmore
Shots: Veila Bio to receive $30M upfront licensing fee, additional payment on development and commercial milestones plus royalties on sales of product post-launch MTPC to get exclusive rights to develop […]readmore